Quantifying benefits and risks of vaccinating Australian children aged six months to four years with trivalent inactivated seasonal influenza vaccine in 2010

H Kelly; D Carcione; G Dowse; P Effler

doi:10.2807/ese.15.37.19661-en

Rapid communications Open Access

Like 0

Download

Quantifying benefits and risks of vaccinating Australian children aged six months to four years with trivalent inactivated seasonal influenza vaccine in 2010
H Kelly¹ , D Carcione² , G Dowse² , P Effler²
View Affiliations Hide Affiliations

Affiliations: ¹ Victorian Infectious Diseases Reference Laboratory, Melbourne, Australia ² Communicable Disease Control Directorate, Department of Health Western Australia, Perth, Australia

Correspondence:
H Kelly
heath.kelly mh.org.au
View Citation Hide Citation

Citation style for this article: Kelly H, Carcione D, Dowse G, Effler P. Quantifying benefits and risks of vaccinating Australian children aged six months to four years with trivalent inactivated seasonal influenza vaccine in 2010. Euro Surveill. 2010;15(37):pii=19661. https://doi.org/10.2807/ese.15.37.19661-en Received: 12 Aug 2010

Abstract

Australian and New Zealand health authorities identified seasonal trivalent inactivated influenza vaccines manufactured by CSL Biotherapies as the probable cause of increased febrile convulsions in children under five within 24 hours of vaccination and recommended against their use in this age group. We quantified the benefit-risk profile of the CSL vaccines using the number needed to vaccinate and suggest they might have caused two to three hospital admissions due to febrile convulsions for every hospital admission due to influenza prevented.